Insights into Company Bills & Payments

Myriad Genetics ↗

Part of Myriad Genetics.

1995 📍 United States NASDAQ MYGN Pharmaceuticals & Healthcare
Search companies

Key Metrics of Myriad Genetics

Revenue₹4,985 Cr▼ 2.1% YoYFY 2016-17
EBITDA₹596 Cr▼ 51.0% YoY
Net profit₹112 Cr▼ 85.8% YoY
Net worth₹4,965 Cr▼ 0.6% YoY
Market cap$638MMYGN · $6.67
Competitors10identified

About Myriad Genetics

Part of Myriad Genetics.

Sectors

Pharmaceuticals & HealthcareFormulations & Contract Manufacturing

Company details

Website
myriad.com
Founded
1995
Listed
Nasdaq: MYGN (since 1995)

Operational Areas of Myriad Genetics

Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing

Company summary

Legal nameMyriad Genetics Inc.
TickerMYGN
ExchangeNasdaq
CountryUnited States
SEC CIK0000899923
Listed since1995
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Websitehttps://myriad.com

US market & SEC filings

MYGN · Nasdaq  ·  SEC CIK 0000899923

Last price · 31 Oct 2026 $6.67 +0.60%
Market cap$638M
P/E—On FY 2023 diluted EPS
Volume1,470,889
SectorHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances
Country · IPOUnited StatesListed 1995

MYGN share price

Premium

Annual results (SEC EDGAR)

Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.

Sign in to continue See plans & pricing
Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Sign in to continue See plans & pricing

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Consolidated accounts · FY 2016-17

Indicative long-term—
Indicative short-term—
Score—
LiquidityAdequate
DirectionStable

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

DefaultNo default on record
Issuer cooperationCooperating
Credit enhancementNone – standalone rating
Information on file33% · missing: Audited financial statements (last 18 months), Capex / investment plans, Lender details, Auditor details, Shareholding pattern, Recent rating review (last 15 months)

Indicative assessment from public data using the published methodology factors; not a credit rating.

Registered office and contact

Registered officeSalt Lake City
GSTIN—
Email—
Websitehttps://myriad.com
Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of Myriad Genetics

Competitors10identified
Countries1most in United States

Top competitors by location

CompanyDescriptionDomainFoundedLocation
Eli Lilly and Company Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare lilly.com — United States
Johnson & Johnson Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare jjmt.com.tw — United States
Procter & Gamble Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare pg.com — United States
Merck & Co. Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare merck.com — United States
Amgen Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare amgen.com 1983 United States
Gilead Sciences Part of Gilead Sciences. gilead.com 1992 United States
Abbott Laboratories Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare abbott.com — United States
Pfizer Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare pfizer.com — United States
Marriott International Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare marriott.com.cn — United States
HCA Healthcare Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare hcahealthcare.com 2011 United States

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Group companies

Part of Myriad Genetics

Business activities and related parties

pharmaceutical industry

Filings

No filings on record yet.